Print full article
The need to inform Australian men about prostate cancer is increasingly important. Each year almost 3300 Australian men die from prostate cancer and more than 21,000 new cases are diagnosed.
Unlike cancers of the bowel, breast and cervix, there is insufficient evidence to support the benefits of population-based screening for prostate cancer using the prostate specific antigen (PSA) test. Current evidence indicates that the PSA test is not suitable for population screening, as the harms (see below) outweigh the benefits. Men who are concerned about prostate cancer should discuss it with their doctor.